Mr. Joseph Papa reports

BAUSCH HEALTH ACQUIRES ETON PHARMACEUTICALS' EM-100 INVESTIGATIONAL EYE DROP FOR THE TREATMENT OF ITCHY EYES ASSOCIATED WITH ALLERGIES

Bausch Health Companies Inc.'s subsidiary, Bausch + Lomb, has acquired the United States rights to Eton Pharmaceuticals' EM-100, an investigational eye drop, that, if approved, will be the first over-the-counter (OTC) preservative-free formulation eye drop for the treatment of ocular itching associated with allergic conjunctivitis. EM-100 has been submitted to the U.S. Food and Drug Administration (FDA) for review.

"In 2019, Bausch Health is pivoting to offense by strategically enhancing our pipeline and portfolio. EM-100 is a new, differentiated eye drop that will complement Bausch + Lomb's broad range of integrated eye health products," said Joseph C. Papa, chairman and chief executive officer of Bausch Health. "If approved, EM-100 will be the first preservative-free allergy eye drop available in the United States and will allow us to better serve the millions of Americans that experience itchy eyes due to allergies."

Eton Pharmaceuticals previously reported positive top-line results from a phase 3 trial in which EM-100 demonstrated statistically significant superiority to placebo, no adverse events and non-inferiority to a comparator product in the treatment of ocular itching.

"We believe that partnering with Bausch + Lomb, a global leader in consumer ophthalmology, will allow us to maximize EM-100's commercial potential and provide broad accessibility for patients," said Sean Brynjelsen, CEO of Eton Pharmaceuticals.

About Bausch Health Companies Inc.

Bausch Health is a global company, with a mission to improve people's lives with its health care products. The company develops, manufactures and markets a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. The company is delivering on its commitments as it builds an innovative company dedicated to advancing global health.

We seek Safe Harbor.